MGTX News and Press, MeiraGTx Holdings plc From 11/14/23

- Received strategic investment from Sanofi purchasing $30 million of ordinary shares of the Company at a price of $7.50 per share in October 2023 - Announced a right of first negotiation (ROFN) with Sanofi for the use of MeiraGTx’s Riboswitch gene regulation technology for c...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

MeiraGTx Holdings plc (MGTX) is expected to report $-0.63 for Q3 2023

2023-11-03 14:08:27 ET DENVER, Colo., Nov 3, 2023 ( www.247marketnews.com )- The following companies were among the listings that we covered this week; Verve Therapeutics Inc (NASDAQ: VERV), Cellectis (NASDAQ: CLLS), Palantir Technologies (NYSE: PLTR), Werewolf Therapeutics (N...

(NewsDirect) Best Growth Stocks, a leading independent research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued a comprehensive analysis on MeiraGTx Holdings plc a vertically integrated, clinical sta...

2023-10-30 12:16:36 ET DENVER, Colo., Oct. 30, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; VYNE Therapeutics Inc (NASDAQ: VYNE), Coherus BioSciences Inc (NASDAQ: CHRS), MeiraGTx Holdings PLC (N...

2023-10-30 08:24:43 ET More on MeiraGTx Seeking Alpha’s Quant Rating on MeiraGTx Historical earnings data for MeiraGTx Financial information for MeiraGTx For further details see: MeiraGTx reports $30 million strategic investment from Sanofi

Sanofi to purchase $30 million of ordinary shares of the Company at a price of $7.50 per share Sanofi to receive a right of first negotiation (ROFN) for the use of MeiraGTx’s Riboswitch gene regulation technology for certain Immunology and Inflammation (I&I) and Central Ner...

LONDON and NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company will exhibit eight posters and deliver one oral presentation at the European Society of Gene and Ce...

2023-08-10 10:50:41 ET MeiraGTx press release ( NASDAQ: MGTX ): Q2 GAAP EPS of -$0.53. Revenue of $3.5M. Cash and cash equivalents were $92.8 million as of June 30, 2023, compared to $115.5 million as of December 31, 2022. For further details see: MeiraGTx GA...